Does the eltrompobag treatment safe or effective for refractory chronic immune thrombocytopenia patients?

Basit Öğe Kaydı
dc.contributor.authorDal, Mehmet Sinan
dc.contributor.authorKarakus, Abdullah
dc.contributor.authorCakar, Merih Kizil
dc.contributor.authorUlu, Bahar Uncu
dc.contributor.authorHattapoglu, Elif
dc.contributor.authorEkmen, Mehmet Onder
dc.contributor.authorUlas, Turgay
dc.date.accessioned2024-04-24T17:33:30Z
dc.date.available2024-04-24T17:33:30Z
dc.date.issued2016
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground: Immune thrombocytopenia (ITP) is a heterogeneous autoimmune disorder characterized by immune-mediated platelet destruction and reduced platelet production. As the pathophysiology of the disease got clear, thrombopoietin receptor (TPO-R) agonists have been preferred in recent years, which seems to be an effective option in the treatment of resistant cases. Eltrombopag, a TPO-R agonist, is a second or third line medical treatment option for adults with chronic ITP. Objective: To determine the efficacy and safety of long-term eltrombopag treatment in treatment-refractory patients with primary ITP was the aim of this study. Materials and Methods: Retrospective data of 34 patients with refractory ITP who were treated with eltrombopag were examined. Efficacy and safety of the eltrombopag treatment was evaluated. Results: The total rate of response was 82%, and the median duration of response defined as the number of the platelets being over 50x10(9)/L was 14 (interquartile range: 7-28) days. In two patients, thrombosis was observed with no other additional risk factors due to or related to thrombosis. Conclusion: In spite of the fact that the responses to eltrombopag were satisfactory, patients need to be monitored closely for increasing platelet counts as well as thromboembolic events.en_US
dc.identifier.endpage18711en_US
dc.identifier.issn1940-5901
dc.identifier.issue9en_US
dc.identifier.scopus2-s2.0-84989171909
dc.identifier.scopusqualityN/A
dc.identifier.startpage18707en_US
dc.identifier.urihttps://hdl.handle.net/11468/20721
dc.identifier.volume9en_US
dc.identifier.wosWOS:000386671100205
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.language.isoenen_US
dc.publisherE-Century Publishing Corpen_US
dc.relation.ispartofInternational Journal of Clinical and Experimental Medicine
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectImmune Thrombocytopeniaen_US
dc.subjectThrombopoietin Receptor Agonisten_US
dc.subjectThrombosisen_US
dc.subjectEltrombopagen_US
dc.titleDoes the eltrompobag treatment safe or effective for refractory chronic immune thrombocytopenia patients?en_US
dc.titleDoes the eltrompobag treatment safe or effective for refractory chronic immune thrombocytopenia patients?
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu